Concerns on Bebtelovimab (LY‐CoV1404) used to neutralize Omicron subvariants

AlexandrosSfakianakis shared this article with you from Inoreader Concerns on Bebtelovimab (LY‐CoV1404) used to neutralize Omicron subvariants via Journal of Medical Virology Abstract Bebtelovimab (LY-CoV1404) is a monoclonal antibody showing remarkable neutralizing capacity against all SARS-CoV-2 variants of concern (VOCs) as of June 2022, including the Omicron variant and its subvariants This article is protected by copyright. All rights reserved. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.